Latest Breaking News On - Annual american academy - Page 1 : vimarsana.com

Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update

First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530.

United statesEmild kakkisDaiichi sankyoJoshua higaDrug administrationContacts ultragenyx pharmaceutical incExchange commissionAmerican academy of neurology meetingUltragenyx pharmaceutical incUdall foundationKyowa kirin coExpansion cohortsDose escalation cohortFinancial data tablesFinancial resultsMonths ended march

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting

Company will host investor call on April 17 at 8:00 a.m. ET to discuss new data from GTX-102 Phase 1/2 clinical study in patients with Angelman syndrome NOVATO, Calif., April 12, 2024 .

United statesKemia olugemoMelanie brandaburRachael elizabeth hawtinCarolyn wangJoshua higaAmerican academy of neurology meetingExchange commissionUltragenyx pharmaceutical incAnnual american academyNeurology meetingClinical activityInvestigational antisense oligonucleotidePatients with angelmanEmerging scienceProteomic profiling

Ultragenyx Pharmaceutical Inc : Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting

Ultragenyx Pharmaceutical Inc : Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesCarolyn wangRachael elizabeth hawtinJoshua higaDennis riedlMelanie brandaburKemia olugemoAmerican academy of neurology meetingUltragenyx pharmaceutical incExchange commissionAnnual american academyNeurology meetingClinical activityInvestigational antisense oligonucleotidePatients with angelmanEmerging science

Jazz to Highlight Narcolepsy and IH Research at AAN 2024

Jazz Pharmaceuticals announced it will present one oral presentation and four poster presentations on narcolepsy and idiopathic hypersomnia.

United statesRob iannoneWorld idiopathic hypersomnia total health modelAmerican academy of neurology meeting in denverAmerican academy of neurology meetingJazz pharmaceuticalsAnnual american academyNeurology meeting

Michael B Gorin, MD, PhD: Interim TEASE-3 Trial Data in Stargardt Disease

Positive interim data from the TEASE-3 clinical trial show gildeuretinol slows the progression of Stargardt Disease for up to six years.

United statesMichaelb gorinAlkeus pharmaceuticalsAmerican academy of ophthalmology meetingDavid geffen school of medicineDavid geffen schoolAnnual american academy